Nucleoside analogues display significant anticancer or antiviral activity by interfering with DNA synthesis. However, there are some serious restrictions to their use, including their rapid metabolism and the induction of resistance. We have discovered that the linkage of nucleoside analogues to squalene leads to amphiphilic molecules that self-organize in water as nanoassemblies of 100-300 nm, irrespective of the nucleoside analogue used. The squalenoyl gemcitabine exhibited superior anticancer activity in vitro in human cancer cells and gemcitabine-resistant murine leukemia cells, and in vivo in experimental leukemia both after intravenous and oral administration. The squalenoylation of other antiretroviral nucleosides also led to more potent drugs when tested in primary cultures of HIV-infected lymphocytes. Thus, the squalenoylation is an original technology platform for generating more potent anticancer and antiviral nanomedicines.

Squalenoyl nanomedicines as potential therapeutics

STELLA, Barbara;ROCCO, Flavio;CATTEL, Luigi
2006-01-01

Abstract

Nucleoside analogues display significant anticancer or antiviral activity by interfering with DNA synthesis. However, there are some serious restrictions to their use, including their rapid metabolism and the induction of resistance. We have discovered that the linkage of nucleoside analogues to squalene leads to amphiphilic molecules that self-organize in water as nanoassemblies of 100-300 nm, irrespective of the nucleoside analogue used. The squalenoyl gemcitabine exhibited superior anticancer activity in vitro in human cancer cells and gemcitabine-resistant murine leukemia cells, and in vivo in experimental leukemia both after intravenous and oral administration. The squalenoylation of other antiretroviral nucleosides also led to more potent drugs when tested in primary cultures of HIV-infected lymphocytes. Thus, the squalenoylation is an original technology platform for generating more potent anticancer and antiviral nanomedicines.
2006
6
2544
2548
Cellular pharmacology; antitumor-activity; gemcitabine; leukemia; elimination; nucleosides; mechanisms; analogs; plasma
COUVREUR P; STELLA B; REDDY LH; HILLAIREAU H; DUBERNET C; DESMAELE D; LEPETRE-MOUELHI S; ROCCO F; DEREUDDRE-BOSQUET N; CLAYETTE P; ROSILIO V; MARSAUD V; RENOIR JM; CATTEL L
File in questo prodotto:
File Dimensione Formato  
Nano Letters def.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 220.58 kB
Formato Adobe PDF
220.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/35750
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 291
  • ???jsp.display-item.citation.isi??? 277
social impact